EirGenix
@eirgenix.com
EirGenix is a global biologics CDMO and biosimilar developer delivering high quality, cost competitive solutions from early development through commercial manufacturing. Founded in 2012, we support pharmaceutical and biotechnology partners worldwide with fully integrated services spanning cell line development, process development, analytical testing, cGMP manufacturing, and ADC development. With expertise in both mammalian and microbial systems, EirGenix provides flexible, scalable, and regulatory ready capabilities designed to accelerate development timelines and ensure reliable global supply. With two state of the art facilities in Taiwan and a growing presence in Europe, EirGenix enables pharmaceutical partners worldwide to accelerate development, reduce cost of goods, and reliably supply biologics for global markets. Our integrated biologics platform supports a broad range of modalities, including monoclonal antibodies, bispecific antibodies, recombinant proteins, fusion proteins, and antibody-drug conjugates (ADCs). Leveraging proprietary expression technologies, robust process development, analytical expertise, and cGMP manufacturing capabilities, we help clients efficiently advance programs from development through commercialization. In addition to CDMO services, EirGenix is also a biosimilar developer with successful experience in product development, regulatory approval, and commercialization. Through flexible partnership models including CDMO, co-development, and licensing, we combine scientific expertise, manufacturing excellence, and global regulatory experience to help partners bring innovative biologics to patients worldwide.
EirGenix's Company Logos
EirGenix's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#0079AF
Deep Cerulean
0, 121, 175
199, 100, 34
100, 31, 0, 31
#FFFFFF
White
255, 255, 255
0, 0, 100
0, 0, 0, 0
#252525
Mine Shaft
37, 37, 37
0, 0, 15
0, 0, 0, 85
About EirGenix
EirGenix, Inc. Established in 2012, EirGenix specializes in a comprehensive suite of offerings, including cell line development, analytical and quality control, and cGMP manufacturing across both mammalian and microbial systems. Their mission centers on enhancing individual and societal well-being by making affordable, high-quality biological drugs accessible to patients.
The company boasts an extensive product pipeline, including versatile candidates like CRM197 carrier protein and a rapid COVID-19 antigen test that delivers results within 10 minutes. EirGenix emphasizes collaboration and client success, aiming to accelerate the drug development process in biotechnology for a healthier future. With state-of-the-art facilities located in Xizhi and Zhubei, EirGenix stands at the forefront of biopharmaceutical innovation, dedicated to improving the quality of life through advanced therapeutics
Company type
Public Company
Year founded
2012
Company size
201-500 employees
